Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors.

Chiyonobu N, Shimada S, Akiyama Y, Mogushi K, Itoh M, Akahoshi K, Matsumura S, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Suganami T, Yamaoka S, Ogawa Y, Tanabe M, Tanaka S.

Am J Pathol. 2018 May;188(5):1213-1224. doi: 10.1016/j.ajpath.2018.01.012. Epub 2018 Feb 16.

PMID:
29454748
2.

DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma.

Mizuno Y, Shimada S, Akiyama Y, Watanabe S, Aida T, Ogawa K, Ono H, Mitsunori Y, Ban D, Kudo A, Arii S, Yamaoka S, Tanabe M, Tanaka S.

Sci Rep. 2018 Jan 8;8(1):106. doi: 10.1038/s41598-017-18323-9.

3.

Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting.

Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N; Liver Cancer Study Group of Japan.

Liver Int. 2018 Mar;38(3):484-493. doi: 10.1111/liv.13670. Epub 2018 Jan 25.

PMID:
29266722
4.

Sequential motion of the ossicular chain measured by laser Doppler vibrometry.

Kunimoto Y, Hasegawa K, Arii S, Kataoka H, Yazama H, Kuya J, Fujiwara K, Takeuchi H.

Acta Otolaryngol. 2017 Dec;137(12):1233-1237. doi: 10.1080/00016489.2017.1357833. Epub 2017 Jul 31.

PMID:
28758555
5.

Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.

Ohata Y, Shimada S, Akiyama Y, Mogushi K, Nakao K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M, Tanaka S.

Mol Cancer Ther. 2017 Jun;16(6):1155-1165. doi: 10.1158/1535-7163.MCT-16-0728. Epub 2017 Feb 28.

6.

Analysis of Direct Simultaneous Measurement of Glottal Airflow Velocity, Subglottal Pressure, and High-Speed Imaging Using Flexible Transnasal Endoscope in a Human Subject.

Kataoka H, Arii S, Fukuhara T, Fujiwara K, Kunimoto Y, Hasegawa K, Takeuchi H.

Yonago Acta Med. 2016 Sep 12;59(3):241-247. eCollection 2016 Sep.

7.

Proteasome activity is required for the initiation of precancerous pancreatic lesions.

Furuyama T, Tanaka S, Shimada S, Akiyama Y, Matsumura S, Mitsunori Y, Aihara A, Ban D, Ochiai T, Kudo A, Fukamachi H, Arii S, Kawaguchi Y, Tanabe M.

Sci Rep. 2016 May 31;6:27044. doi: 10.1038/srep27044.

8.

Characteristic oxidation behavior of β-cyclocitral from the cyanobacterium Microcystis.

Tomita K, Hasegawa M, Arii S, Tsuji K, Bober B, Harada K.

Environ Sci Pollut Res Int. 2016 Jun;23(12):11998-2006. doi: 10.1007/s11356-016-6369-y. Epub 2016 Mar 10.

PMID:
26961531
9.

Genome-wide DNA methylation analysis in hepatocellular carcinoma.

Yamada N, Yasui K, Dohi O, Gen Y, Tomie A, Kitaichi T, Iwai N, Mitsuyoshi H, Sumida Y, Moriguchi M, Yamaguchi K, Nishikawa T, Umemura A, Naito Y, Tanaka S, Arii S, Itoh Y.

Oncol Rep. 2016 Apr;35(4):2228-36. doi: 10.3892/or.2016.4619. Epub 2016 Feb 11.

PMID:
26883180
10.

Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.

Ito H, Tanaka S, Akiyama Y, Shimada S, Adikrisna R, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Yamaoka S, Tanabe M.

PLoS One. 2016 Jan 14;11(1):e0146564. doi: 10.1371/journal.pone.0146564. eCollection 2016.

11.

Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors.

Akahoshi K, Tanaka S, Mogushi K, Shimada S, Matsumura S, Akiyama Y, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M.

J Gastroenterol. 2016 Sep;51(9):910-22. doi: 10.1007/s00535-015-1159-8. Epub 2016 Jan 6.

PMID:
26739296
12.

CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells.

Katsuta E, Tanaka S, Mogushi K, Shimada S, Akiyama Y, Aihara A, Matsumura S, Mitsunori Y, Ban D, Ochiai T, Kudo A, Fukamachi H, Tanaka H, Nakayama K, Arii S, Tanabe M.

Int J Oncol. 2016 Feb;48(2):657-69. doi: 10.3892/ijo.2015.3299. Epub 2015 Dec 18.

PMID:
26691441
13.

Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.

Nakao K, Tanaka S, Miura T, Sato K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M.

Cancer Sci. 2015 Aug;106(8):1016-22. doi: 10.1111/cas.12701. Epub 2015 Jun 25.

14.

EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma.

Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, Kitaichi T, Yamada N, Iwai N, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Tanaka S, Arii S, Itoh Y.

Cancer Sci. 2015 Jul;106(7):929-37. doi: 10.1111/cas.12694. Epub 2015 Jun 5.

15.

Cyanobacterial blue color formation during lysis under natural conditions.

Arii S, Tsuji K, Tomita K, Hasegawa M, Bober B, Harada K.

Appl Environ Microbiol. 2015 Apr;81(8):2667-75. doi: 10.1128/AEM.03729-14. Epub 2015 Feb 6.

16.

DNA methylation at hepatitis B viral integrants is associated with methylation at flanking human genomic sequences.

Watanabe Y, Yamamoto H, Oikawa R, Toyota M, Yamamoto M, Kokudo N, Tanaka S, Arii S, Yotsuyanagi H, Koike K, Itoh F.

Genome Res. 2015 Mar;25(3):328-37. doi: 10.1101/gr.175240.114. Epub 2015 Feb 4.

17.

Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M.

Hepatol Res. 2015 Jan;45(2). doi: 10.1111/hepr.12464.

PMID:
25625806
18.

A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.

Matsunaga H, Tanaka S, Aihara A, Ogawa K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Arii S, Tanabe M.

Ann Surg Oncol. 2015 Sep;22(9):3079-86. doi: 10.1245/s10434-014-4292-3. Epub 2014 Dec 19.

PMID:
25524010
19.

Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection.

Okajima C, Arii S, Tanaka S, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M.

Am J Surg. 2015 Jan;209(1):199-205. doi: 10.1016/j.amjsurg.2014.03.009. Epub 2014 May 23.

PMID:
25312843
20.

Age-related clinicopathologic and molecular features of patients receiving curative hepatectomy for hepatocellular carcinoma.

Katsuta E, Tanaka S, Mogushi K, Matsumura S, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Tanabe M, Arii S.

Am J Surg. 2014 Sep;208(3):450-6. doi: 10.1016/j.amjsurg.2014.01.015. Epub 2014 May 4.

PMID:
24972857
21.

Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.

Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Nakamoto Y, Yamamoto M, Takayama T, Arii S, Wang X, Kaneko S.

Hepatology. 2014 Nov;60(5):1674-85. doi: 10.1002/hep.27093. Epub 2014 Sep 29.

22.

Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function?

Kudo A, Matsumura S, Ban D, Irie T, Ochiai T, Tanaka S, Arii S, Tanabe M.

Hepatol Res. 2014 Dec;44(14):E437-46. doi: 10.1111/hepr.12335. Epub 2014 May 6.

PMID:
24690156
23.

[Curative resection of stage IV advanced gallbladder cancer following combined treatment with gemcitabine and CDDP].

Adikrisna R, Nakamura N, Irie T, Matsumura S, Tanaka S, Arii S.

Gan To Kagaku Ryoho. 2014 Jan;41(1):117-20. Review. Japanese.

PMID:
24423965
24.

Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study.

Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, Asahina Y, Enomoto N, Arii S, Izumi N.

Oncology. 2014;86(1):53-62. doi: 10.1159/000356643. Epub 2014 Jan 8.

PMID:
24401597
25.

EpCAM-targeted therapy for human hepatocellular carcinoma.

Ogawa K, Tanaka S, Matsumura S, Murakata A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M, Arii S.

Ann Surg Oncol. 2014 Apr;21(4):1314-22. doi: 10.1245/s10434-013-3430-7. Epub 2013 Dec 27.

PMID:
24370904
26.

Sequential multipoint motion of the tympanic membrane measured by laser Doppler vibrometry: preliminary results for normal tympanic membrane.

Kunimoto Y, Hasegawa K, Arii S, Kataoka H, Yazama H, Kuya J, Kitano H.

Otol Neurotol. 2014 Apr;35(4):719-24. doi: 10.1097/MAO.0000000000000242.

PMID:
24317215
27.

Favorable response after gemcitabine-radiotherapy for invasive pancreatic intraductal papillary mucinous neoplasm: a case report.

Ochiai T, Igari K, Furuyama T, Ito H, Mitsunori Y, Aihara A, Kumagai Y, Iida M, Odajima H, Tanaka S, Arii S, Yamazaki S.

Int Surg. 2013 Oct-Dec;98(4):340-5. doi: 10.9738/INTSURG-D-13-00031.1.

28.

[A case ectopic hepatocellular carcinoma with peritoneal dissemination].

Nakamura N, Irie T, Tanaka S, Arii S.

Nihon Shokakibyo Gakkai Zasshi. 2013 Nov;110(11):1968-75. Japanese.

PMID:
24189826
29.

Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis.

Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Ochiai T, Nakamura N, Arii S, Tanabe M.

J Gastroenterol. 2014 Sep;49(9):1352-61. doi: 10.1007/s00535-013-0899-6. Epub 2013 Oct 18.

PMID:
24136219
30.

Anatomic resection reduces the recurrence of solitary hepatocellular carcinoma ≤5 cm without macrovascular invasion.

Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, Nakamura N, Arii S.

Am J Surg. 2014 Jun;207(6):863-9. doi: 10.1016/j.amjsurg.2013.06.009. Epub 2013 Oct 8.

PMID:
24112679
31.

High resectability of colorectal liver metastases with aggressive chemotherapy in the era of molecular target-based agents.

Ochiai T, Ohta K, Iida M, Kumagai Y, Mitsunori Y, Aihara A, Noguchi N, Tanaka S, Arii S, Yamazaki S.

Hepatogastroenterology. 2013 Jul-Aug;60(125):955-60. doi: 10.5754/hge121213.

PMID:
23803362
32.

Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count.

Ikeda N, Imanishi H, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Saito M, Iijima H, Iimuro Y, Fujimoto J, Yamamoto S, Hirota S, Kudo M, Arii S, Nishiguchi S.

Hepatol Res. 2014 Aug;44(8):829-36. doi: 10.1111/hepr.12184. Epub 2013 Aug 7.

PMID:
23763386
33.

Severe postoperative hemorrhage caused by antibody-mediated coagulation factor deficiencies: report of two cases.

Miura T, Ban D, Koyama T, Kudo A, Ochiai T, Irie T, Nakamura N, Tanaka S, Arii S.

Surg Today. 2014 May;44(5):976-81. doi: 10.1007/s00595-013-0584-7. Epub 2013 May 23.

PMID:
23695294
34.

Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment.

Tamura Y, Suda T, Arii S, Sata M, Moriyasu F, Imamura H, Kawasaki S, Izumi N, Takayama T, Kokudo N, Yamamoto M, Iijima H, Aoyagi Y.

Dig Dis Sci. 2013 Aug;58(8):2406-12. doi: 10.1007/s10620-013-2661-6. Epub 2013 Apr 18.

PMID:
23595518
35.

The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma.

Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S, Inazawa J.

PLoS One. 2013;8(3):e60155. doi: 10.1371/journal.pone.0060155. Epub 2013 Mar 27.

36.

Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study.

Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S.

J Gastroenterol. 2014 Mar;49(3):502-10. doi: 10.1007/s00535-013-0791-4. Epub 2013 Mar 30.

PMID:
23543312
37.

Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course.

Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Nakayama K, Tanaka H, Yamaoka S, Arii S.

Hepatology. 2013 Jul;58(1):218-28. doi: 10.1002/hep.26345. Epub 2013 May 27.

PMID:
23447025
38.

Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm.

Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan.

Liver Int. 2013 May;33(5):762-70. doi: 10.1111/liv.12130. Epub 2013 Feb 28.

PMID:
23445409
39.

Up-regulation of dbpA mRNA in hepatocellular carcinoma associated with metabolic syndrome.

Obulhasim G, Yasen M, Kajino K, Mogushi K, Tanaka S, Mizushima H, Tanaka H, Arii S, Hino O.

Hepatol Int. 2013 Mar;7(1):215-25. doi: 10.1007/s12072-012-9357-4. Epub 2012 Mar 13.

PMID:
26201636
40.

Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan.

Kudo M, Matsui O, Sakamoto M, Kitao A, Kim T, Ariizumi S, Ichikawa T, Kobayashi S, Imai Y, Izumi N, Fujinaga Y, Arii S.

Oncology. 2013;84 Suppl 1:21-7. doi: 10.1159/000345885. Epub 2013 Feb 20.

PMID:
23428854
41.

Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma.

Dohi O, Yasui K, Gen Y, Takada H, Endo M, Tsuji K, Konishi C, Yamada N, Mitsuyoshi H, Yagi N, Naito Y, Tanaka S, Arii S, Yoshikawa T.

Int J Oncol. 2013 Feb;42(2):411-8. doi: 10.3892/ijo.2012.1724. Epub 2012 Nov 30.

42.

Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling.

Katayama Y, Maeda M, Miyaguchi K, Nemoto S, Yasen M, Tanaka S, Mizushima H, Fukuoka Y, Arii S, Tanaka H.

Oncol Lett. 2012 Oct;4(4):817-823. Epub 2012 Jul 18.

43.

Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images.

Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Koda W, Gabata T, Yamashita T, Kaneko S, Nakanuma Y, Kita R, Arii S.

Radiology. 2012 Dec;265(3):780-9. doi: 10.1148/radiol.12120226.

44.

Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: clinical and biological significance.

Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanaka H, Arii S.

Hepatology. 2013 Apr;57(4):1436-47. doi: 10.1002/hep.26122. Epub 2013 Jan 25.

PMID:
23150500
45.

Morphological and microarray analyses of human hepatocytes from xenogeneic host livers.

Tateno C, Miya F, Wake K, Kataoka M, Ishida Y, Yamasaki C, Yanagi A, Kakuni M, Wisse E, Verheyen F, Inoue K, Sato K, Kudo A, Arii S, Itamoto T, Asahara T, Tsunoda T, Yoshizato K.

Lab Invest. 2013 Jan;93(1):54-71. doi: 10.1038/labinvest.2012.158. Epub 2012 Nov 12.

46.

Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case.

Ochiai T, Masuda T, Yagi M, Kasai R, Furuyama T, Tsukamoto K, Ito H, Igari K, Aihara A, Kumagai Y, Iida M, Odajima H, Tanaka S, Arii S, Yamazaki S.

Int Surg. 2012 Jan-Mar;97(1):6-13. doi: 10.9738/CC88.1.

47.

Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.

Endo M, Yasui K, Zen Y, Gen Y, Zen K, Tsuji K, Dohi O, Mitsuyoshi H, Tanaka S, Taniwaki M, Nakanuma Y, Arii S, Yoshikawa T.

Liver Int. 2013 Jan;33(1):105-17. doi: 10.1111/liv.12005. Epub 2012 Oct 22.

PMID:
23088494
48.

Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.

Mayinuer A, Yasen M, Mogushi K, Obulhasim G, Xieraili M, Aihara A, Tanaka S, Mizushima H, Tanaka H, Arii S.

Ann Surg Oncol. 2013 Jan;20(1):305-17. doi: 10.1245/s10434-012-2395-2. Epub 2012 Oct 13.

49.

[A case of pancreatic mucinous carcinoma invading the common bile duct with obstructive jaundice].

Nakamura N, Irie T, Tanaka S, Teramoto K, Arii S.

Nihon Shokakibyo Gakkai Zasshi. 2012 Oct;109(10):1799-806. Japanese.

PMID:
23047639
50.

Combined resection of a tumor and the inferior vena cava: report of two cases.

Jibiki M, Inoue Y, Kudo T, Toyofuku T, Saito K, Kihara K, Kudo A, Ban D, Arii S.

Surg Today. 2014 Jan;44(1):166-70. doi: 10.1007/s00595-012-0337-z. Epub 2012 Sep 22.

Supplemental Content

Support Center